, Volume 17, Issue 3, pp 207–210 | Cite as

Spotlight on Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis

Adis Spotlight


Glatiramer acetate (Copaxone®) is a synthetic copolymer composed of a random mixture of four amino acids that modifies the immune response that results in the CNS inflammation, demyelination and axonal loss characteristic of relapsing-remitting multiple sclerosis (RRMS).

In three randomised, double-blind trials in patients with RRMS, subcutaneous glatiramer acetate 20 mg/day was significantly more effective than placebo for the primary outcome measure of each trial (mean relapse rate, proportion of relapse-free patients and number of gadolinium-enhancing lesions on magnetic resonance imaging [MRI] scans). The mean relapse rate was significantly reduced at endpoint (approximately one-third less) in the two larger trials (the US pivotal trial [primary endpoint] and the European/Canadian study [tertiary endpoint]) in patients receiving glatiramer acetate compared with those receiving placebo. The rate was 78% less for glatiramer acetate than placebo patients in the pilot trial that investigated a slightly different patient population. Glatiramer acetate significantly decreased disease activity and burden of disease, as assessed in the European/Canadian study using a range of MRI measures. Patients with RRMS treated with glatiramer acetate in the US trial were significantly more likely to experience improved disability (whereas placebo recipients were more likely to experience worsening disability) and their overall disability status was significantly improved compared with placebo recipients. Data from the active-treatment extension of the US trial suggest that glatiramer acetate has sustained clinical benefits up to 8 years.

Glatiramer acetate was generally well tolerated; the most commonly reported treatment-related adverse events were localised injection-site reactions and transient post-injection systemic reactions. Both reactions were generally mild and self limiting but were responsible for the majority of withdrawals from treatment (up to 6.5% and 3.5%, respectively). Glatiramer acetate is not associated with the influenza-like syndrome or neutralising antibodies that are reported in patients treated with interferon-β for RRMS.

The cost effectiveness of glatiramer acetate has yet to be definitively determined as assessment of available data is confounded by very different models, data sources and assumptions.

In conclusion, glatiramer acetate has shown efficacy in well controlled clinical trials in patients with RRMS; it reduces relapse rate and decreases MRI-assessed disease activity and burden. It is generally well tolerated and is not associated with the influenza-like symptoms and formation of neutralising antibodies seen with the interferons-β. Based on available data and current management guidelines, glatiramer acetate is a valuable first-line treatment option for patients with RRMS.


Expand Disability Status Scale Glatiramer Acetate Glatiramer Copaxone Glatiramer Acetate Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The full text article in CNS Drugs 2002 Dec; 16 (12): 825–850 was reviewed by: R. Arnon, Department of Immunology, Weizmann Institute of Science, Rehovot, Israel; M. Filippi, Department of Neuroscience, Scientific Institute Ospendale San Raffaele, Milan, Italy; M. S. Freedman, Multiple Sclerosis Research Clinic, The Ottawa Hospital, Ottawa, Canada; G. Giovannoni, Department of Neurochemistry, University of London, London, UK; K. P. Johnson, Department of Neurology, University of Maryland, Baltimore, Maryland, USA; D. Teitelbaum, Department of Immunology, Weizmann Institute of Science, Rehovot, Israel; B. Weinstock-Guttman, Baird Center for Multiple Sclerosis, The State University of New York, University at Buffalo, Buffalo, New York, USA.


  1. 1.
    Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2001; 2(7): 1149–65PubMedCrossRefGoogle Scholar
  2. 2.
    Teitelbaum D, Sela M, Arnon R. Copolymer 1 from the laboratory to FDA. Isr J Med Sci 1997 Apr; 33(4): 280–4PubMedGoogle Scholar
  3. 3.
    Neuhaus O, Farina C, Wekerle H, et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001 Mar 27; 56(6): 702–8PubMedCrossRefGoogle Scholar
  4. 4.
    Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000 Dec 12; 55(11): 1704–14PubMedCrossRefGoogle Scholar
  5. 5.
    Hohlfeld R. Therapeutic strategies in multiple sclerosis. I. Immunotherapy. Philos Trans R Soc Lond B Biol Sci 1999 Oct 29; 354(1390): 1697–710PubMedCrossRefGoogle Scholar
  6. 6.
    Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A 2000 Jun 20; 97(13): 7452–7PubMedCrossRefGoogle Scholar
  7. 7.
    Chen M, Johnson KP, Martin R, et al. Glatiramer acetate treatment induces a Th1 to Th2 cytokine shift in multiple sclerosis [abstract no. 224]. Ann Neurol 2000 Sep; 48: 475Google Scholar
  8. 8.
    Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000 Apr; 105(7): 967–76PubMedCrossRefGoogle Scholar
  9. 9.
    Farina C, Then Bergh F, Albrecht H, et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-response in blood cells. Brain 2001 Apr; 124(Pt 4): 705–19PubMedCrossRefGoogle Scholar
  10. 10.
    Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Thl to Th2/Th3 immune-deviation. J Neuroimmunol 1998 Dec 1; 92(1-2): 113–21PubMedCrossRefGoogle Scholar
  11. 11.
    Aharoni R, Teitelbaum D, Leitner O, et al. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A 2000 Oct 10; 97(21): 11472–7PubMedCrossRefGoogle Scholar
  12. 12.
    Teitelbaum D, Milo R, Arnon R, et al. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A 1992 Jan 1;89(1): 137–41PubMedCrossRefGoogle Scholar
  13. 13.
    Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000 Jun 20; 97(13): 7446–51PubMedCrossRefGoogle Scholar
  14. 14.
    Chen M, Dhib-Jalbut S. Glatiramer acetate (GA)-reactive T-cells produce brain-derived neurotrophic factor (BDNF) [abstract no. P328]. European/American Committee for Treatment and Research in Multiple Sclerosis (Ectrims/Actrims); 2002; Baltimore, Maryland, USAGoogle Scholar
  15. 15.
    Stadelmann C, Kerschensteiner M, Misgeld T, et al. BDNF and gpl45trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75–85PubMedCrossRefGoogle Scholar
  16. 16.
    Ziemssen T, Kuempfel T, Klinkert W, et al. Glatiramer acetate-specific T cell lines produce brain-derived neurotrophic factor (BDNF) after activation upon antigen challenge in vitro: a novel mechanism of action? [abstract]. Neurology 2002; 58Suppl. 3: A326Google Scholar
  17. 17.
    Johnson KP, Teitelbaum D, Arnon R, et al. Antibodies to copolymer 1 do not interfere with its clinical effect: US Phase III Coplymer-1 Study Group [abstract]. Ann Neurol 1995 Dec; 38: 973Google Scholar
  18. 18.
    Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001 Apr 2; 115(1-2): 152–60 © Adis Data Information BV 2003. All rights reserved.PubMedCrossRefGoogle Scholar
  19. 19.
    Lobel E, Riven-Kreitman R, Amselem A, et al. Copolymer-1. Drugs Future 1996; 21(2): 131–4Google Scholar
  20. 20.
    Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis: European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001 Mar; 49(3): 290–7PubMedCrossRefGoogle Scholar
  21. 21.
    Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987 Aug 13; 317(7): 408–14PubMedCrossRefGoogle Scholar
  22. 22.
    Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995 Jul; 45: 1268–76PubMedCrossRefGoogle Scholar
  23. 23.
    Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 2001 Aug 28; 57(4): 731–3PubMedCrossRefGoogle Scholar
  24. 24.
    Johnson KP, Brooks B, Ford CC, et al. Results of the long-term (eight-year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis [abstract no. A458]. Neurology 2002 Apr; 58Suppl. 3: A458Google Scholar
  25. 25.
    Bose U, Ladkani D, Burrell A, et al. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Drug Assess 2002; 5 (Pt 1): 67–79Google Scholar
  26. 26.
    National Institute for Clinical Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Technology Appraisal Guidance No. 32 2002 Jan, 1-22Google Scholar
  27. 27.
    Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years: Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000 Aug; 6(4): 255–66PubMedGoogle Scholar
  28. 28.
    Teva Pharmaceutical Industries L. Copaxone: Prescribing information [online]. 2002Google Scholar
  29. 29.
    Korczyn AD, Nisipeanu P. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. J Neurol 1996 Apr; 243(4 Suppl. 1): S23–6PubMedCrossRefGoogle Scholar
  30. 30.
    Bayerl C, Bohland P, Jung EG. Systemic reaction to glatiramer acetate. Contact Dermatitis 2000 Jul; 43(1): 62–3PubMedGoogle Scholar
  31. 31.
    Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001; 24(13): 979–90PubMedCrossRefGoogle Scholar
  32. 32.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 Mar; 39(3): 285–94PubMedCrossRefGoogle Scholar
  33. 33.
    Milo R, Panitch H. Glatiramer acetate or interferon-beta for multiple sclerosis? A guide to drug choice. CNS Drugs 1999; 11(4): 289–306CrossRefGoogle Scholar
  34. 34.
    PRISMS Study Group (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 Nov 7; 352: 1498–504CrossRefGoogle Scholar
  35. 35.
    The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 Apr; 43: 655–61CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Adis International LimitedMairangi BayNew Zealand

Personalised recommendations